The Makings of a Tumor Rejection Antigen
- 1 September 1999
- Vol. 11 (3), 263-270
- https://doi.org/10.1016/s1074-7613(00)80101-6
Abstract
No abstract availableThis publication has 72 references indexed in Scilit:
- A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutationEuropean Journal of Immunology, 1999
- The Emerging Role of CTLA-4 as an Immune AttenuatorImmunity, 1997
- Tumor Eradication by Wild-type p53-specific Cytotoxic T LymphocytesThe Journal of Experimental Medicine, 1997
- Implications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunology Today, 1997
- Escape of Thymocytes and Mature T Cells from Clonal Deletion Due to Limiting Tolerogen Expression LevelsCellular Immunology, 1994
- In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.The Journal of Experimental Medicine, 1994
- A first or dominant immunization. I. Suppression of simultaneous cytolytic T cell responses to unrelated alloantigens.The Journal of Experimental Medicine, 1993
- An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues.The Journal of Experimental Medicine, 1993
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Antigen Recognition by Class I-Restricted T LymphocytesAnnual Review of Immunology, 1989